Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Protein and Fibre Impact on Human Surrogate Markers of Health (PROFIBRE)

16 november 2026 bijgewerkt door: Örebro University, Sweden

A cross-over dietary intervention study with healthy participants (age 50-70 years old) will be conducted. Participants will receive plant-based protein-rich snacks with high or low dietary fibre content for 4 weeks. The goal of this project is to evaluate the impact of pea protein in combination with lower or higher dietary fibre intake on surrogate markers of metabolic, gut, and mental health.

Studie Overzicht

Gedetailleerde beschrijving

The cross-over dietary intervention study will last 16 weeks and comprises 14 study visits, along with 2 screening visits to assess participant eligibility. Participants will be selected based on their Prevotella-to-Bacteroides ratio (high or low) and randomly assigned to one of the intervention arms. Throughout the study, blood, urine, stool, and exhaled breath samples will be collected. Body measurements will be obtained, and functional magnetic resonance imaging (fMRI) scans of the brain will be conducted. Data about food habits, physical activity, gastrointestinal symptoms, stool frequency and consistency, will be collected weekly using designated questionnaires. Questionnaires evaluating sleep, perceived stress as well as anxiety and depression will be collected at each fMRI visit. Participants will receive protein-rich snacks with high or low dietary fibre content during the two 4-week intervention periods (cross-over design). The snacks are plant-based, have a high protein content and different amounts of dietary fiber. After the 1st intervention phase participants will enter a minimum 4-week wash-out period with no intervention or questionnaires before starting the 2nd intervention phase. Considering the protein provided by both the habitual diet and the study products, participants are expected to consume more than 1.4 g of protein per kilogram of body weight per day. For dietary fibre intake, individuals with a habitual intake of 15 to 25 g per day will be eligible for inclusion. Consequently, the lower-fibre study product is expected to increase total fibre intake to approximately the recommended minimum level of 30 g per day, whereas the higher-fibre study product is anticipated to result in a substantially greater fibre intake.

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Örebro County
      • Örebro, Örebro County, Zweden, 70362
        • Werving
        • Campus USÖ, Örebro University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

50 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age 50-70 years old
  2. Body mass index (BMI) 18,5-32 kg/m2
  3. Body weight of 50-90 kg
  4. Weight stable within the previous 3 months
  5. Maintenance of the usual physical activity habits during the study
  6. Prevotella and Bacteroides profile determined by qPCR.

Exclusion Criteria:

  1. Acute chronic disease, inflammatory or functional gastrointestinal diseases and any other disease or disorder that could affect the outcome of the study
  2. Use of a medication that may interfere the study outcome
  3. Eating disorder
  4. Being vegan
  5. Usage of protein supplements during the study, including protein bars or protein enriched foods
  6. Usage of fibre supplements or high intake of food groups/ingredients that could affect the outcome of the study
  7. High protein intake
  8. Use of antibiotic medication during the last 3 months prior the first visit
  9. Trying to lose weight
  10. Trying to gain muscle mass
  11. Use of laxative or anti-diarrhoea medication within the past 3 months before the study
  12. Regular consumption of probiotic or prebiotic product for the past 6 weeks before the study
  13. Special diet that is considered to affect the study participation and/or study results, for example, high protein diets
  14. More than 5 h of moderate-vigorous exercise per week
  15. Intolerance to dietary supplements that will be used in the study
  16. Smoking
  17. Drinks more than 9 standard cups of alcohol per week and/or more than 3 standard cups alcohol per occasion
  18. Cerebral bleeding or history of cerebral bleeding
  19. Claustrophobia
  20. Inability to lay still for a longer time (e.g., due to tremor)
  21. In operated apparatus (e.g., pacemaker), as it interferes with MR imaging
  22. Aneurysm clips in the head
  23. Shunts in the head
  24. Grenade-splinter or metal-splinter in the body (e.g., eyes)
  25. Metal or electrodes in the body (e.g., temp-catheter, aorta stent, cochlea implant)
  26. Comprehensive tooth implants or prosthesis aa. Operated in the head bb. Operated in the heart cc. Swallowed a video-capsule, which may still be in the GI tract

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A: High-low

Participants will receive protein-rich snacks with a high dietary fibre content for 4 weeks, followed by a 4-week washout period and then 4 weeks of protein-rich snacks with a low dietary fibre content.

Participants will receive a protein-rich snack with high dietary fibre content for 4 weeks as follows:

  • Protein in g/day from the snack: up to 40 g.
  • Dietary fibre g/day from the snack: up to 22 g. Participants will consume the intervention snack products for up to 3 times a day while maintaining an isocaloric diet and keeping the diet from the run-in period.

Participants will receive a protein-rich snack with low dietary fibre content for 4 weeks as follows:

  • Protein in g/day from the snack: up to 40 g.
  • Dietary fibre g/day from the snack: up to 6 g. Participants will consume the intervention snack products for up to 3 times a day while maintaining an isocaloric diet and keeping the diet from the run-in period.
Experimenteel: Arm B: Low-high

Participants will receive protein-rich snacks with a low dietary fibre content for 4 weeks, followed by a 4-week washout period and then 4 weeks of protein-rich snacks with a high dietary fibre content.

Participants will receive a protein-rich snack with high dietary fibre content for 4 weeks as follows:

  • Protein in g/day from the snack: up to 40 g.
  • Dietary fibre g/day from the snack: up to 22 g. Participants will consume the intervention snack products for up to 3 times a day while maintaining an isocaloric diet and keeping the diet from the run-in period.

Participants will receive a protein-rich snack with low dietary fibre content for 4 weeks as follows:

  • Protein in g/day from the snack: up to 40 g.
  • Dietary fibre g/day from the snack: up to 6 g. Participants will consume the intervention snack products for up to 3 times a day while maintaining an isocaloric diet and keeping the diet from the run-in period.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Microbial metabolites in feces (Targeted metabolomics)
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

To evaluate the interaction between microbiota enterotypes (Prevotella vs. Bacteroides) and a higher-protein diet containing distinct amounts of dietary fibre on microbial metabolites in feces, including propionate, butyrate, acetate, valerate, isovalerate, isobutyrate, indole-3-butyrate, indole-3-propionate, and indole-3-acetate.

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Microbial metabolites in plasma (Targeted metabolomics)
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

To evaluate the interaction between microbiota enterotypes (Prevotella vs. Bacteroides) and a higher-protein diet containing distinct amounts of dietary fibre on microbial metabolites in plasma, including propionate, butyrate, acetate, valerate, isovalerate, isobutyrate, indole-3-butyrate, indole-3-propionate, and indole-3-acetate in their native or metabolised forms.

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Faecal metabolomics (gut-derived or endogenous metabolites)
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

To determine whether the intervention and microbiota enterotypes influence other classes of gut-derived or endogenous metabolites, including carnitines, fatty acids, glycerolipids and phospholipids, sphingolipids, sterol and prenol lipids, amino acids, sugars, and other organic acids will be measured in feces.

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.
Plasma metabolomics (gut-derived or endogenous metabolites)
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

To determine whether the intervention and microbiota enterotypes influence other classes of gut-derived or endogenous metabolites, including carnitines, fatty acids, glycerolipids and phospholipids, sphingolipids, sterol and prenol lipids, amino acids, sugars, and other organic acids will be measured in plasma.

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Faecal microbiota profiling
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

To determine whether the intervention affected microbiota composition and function, faeces samples will be analysed by shotgun metagenomics, next-generation-sequencing (NGS) or by Illumina 16S rRNA amplicon sequencing, to produce relative abundance information for all genes, functions and organisms for a precise strain-level and functional annotation of the microbiome.

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Gut health status - Bristol Stool Scale
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.

To asses whether the intervention and the microbiota enterotype had an effect on the colonic transit time, The Bristol Stool Scale (BSS) diary will be used. Participants will receive a diary to fill in the frequency of evacuation and consistency of the faeces. The BSS is a validated 7-point visual and descriptive ordinal scale used to classify the consistency of human feces. Scores range from Type 1 (separate hard lumps, indicating constipation) to Type 7 (watery, entirely liquid stool, indicating diarrhea), where Types 3 and 4 represent normal stool consistency.

From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.
Gut health status - The Gastrointestinal Symptom Rating Scale
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.

To asses whether the intervention and the microbiota enterotypes had an effect on gastrointestinal symptoms, The Gastrointestinal Symptom Rating Scale (GSRS) will be used. The rating scale consists of 15 items, evaluating gastrointestinal symptoms across 5 subscales: Reflux (2 items), Abdominal Pain (3 items), Indigestion (4 items), Diarrhea (3 items), and Constipation (3 items). Each item is rated on a 7-point Likert scale ranging from 1 (no symptoms) to 7 (severe symptoms). Domain scores are calculated as the average of the items within that domain, yielding a score range of 1 to 7 per subscale, where higher scores indicate greater symptom severity.

From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.
Concentration of faecal calprotectin
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 7 scheduled study visits across two intervention periods separated by a 4-week washout period.

To asses whether the intervention and the microbiota enterotypes had an effect on gut inflammation, calprotectin will be measured in the participant's faeces as a surrogate health marker for gut inflammation.

From enrollment through study completion (up to 16 weeks); assessed at 7 scheduled study visits across two intervention periods separated by a 4-week washout period.
Inter-individual glucose response profiles
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 2 scheduled study visits across two intervention periods separated by a 4-week washout period (from visit 4 onwards for max. 14 days, and from visit 11 onwards for max. 14 days).

To asses whether the intervention and the microbiota enterotypes had an effect on glucose levels via continuous glucose monitoring (CGM).

From enrollment through study completion (up to 16 weeks); assessed at 2 scheduled study visits across two intervention periods separated by a 4-week washout period (from visit 4 onwards for max. 14 days, and from visit 11 onwards for max. 14 days).
Breath metabolomics
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Screening to explore potential associations with gut-related function.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
Urine metabolomics
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Urine samples will be analysed using targeted and untargeted metabolomics

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.
Urine clinical markers for protein intake compliance
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Urine samples will be used to measure clinical markers of protein intake compliance (urea, creatine, and creatinine)

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Blood clinical markers for protein intake compliance
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Blood samples will be used to measure clinical markers of protein intake compliance (urea, creatine, and creatinine)

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Resting-state brain activity and structure
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

To investigate whether the intervention affects resting-state brain activity and structure using functional MRI (fMRI)

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
Mental health status - perceived stress
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Stress will be evaluated using the Perceived Stress Scale (PSS). This scale is a 10-item self-report questionnaire assessing the degree to which life situations over the past month are appraised as stressful, unpredictable, or uncontrollable. Each item is scored on a 5-point Likert scale ranging from 0 (never) to 4 (very often), with positive items reverse-scored. Items are summed to yield a single total score ranging from 0 to 40, where higher scores indicate greater levels of perceived stress (0-13: Low stress; 14-26: Moderate stress; 27-40: High perceived stress).

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
Mental Health status - Sleep quality
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

To assess sleep quality over the period of the intervention we will use the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-administered questionnaire. The items are combined to generate 7 component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction), each rated from 0 to 3, yielding a single global score ranging from 0 to 21, where higher scores indicate worse sleep quality (a global score greater than 5 indicates severe difficulties in at least two components).

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
Mental health status - depression and anxiety
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Symptoms of depression and anxiety will be evaluated using the Hospital Anxiety and Depression Scale (HADS40). HADS40 is a 14-item self-rating questionnaire divided into two 7-item subscales: Anxiety (HADS-A) and Depression (HADS-D). Each item is scored from 0 to 3, yielding a final score range of 0 to 21 for each subscale, where higher scores indicate greater symptom severity (0-7: Normal; 8-10: Borderline abnormal; 11-21: Abnormal).

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
Dried blood spots microbial metabolite analyses
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Capillary blood samples will be collected using dried blood spot cards to optimize a simpler protocol for metabolomic analysis, to facilitate sample handling and enable more efficient analyses in future studies.

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Physical activity
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will fill in the International Physical Activity Questionnaire (IPAQ) for monitoring physical activity and inactivity. The IPAQ is a 7-item self-report survey used to record the frequency and duration of walking, moderate-intensity, and vigorous-intensity physical activities over the previous 7 days. According to the official IPAQ scoring protocol, responses are weighted by energy requirements to calculate a weekly total physical activity volume expressed in Metabolic Equivalent of Task (MET)-minutes per week (walking = 3.3 METs, moderate activity = 4.0 METs, vigorous activity = 8.0 METs), where higher MET-minute values reflect greater energy expenditure and overall physical activity.

From enrollment through study completion (up to 16 weeks); assessed at 14 scheduled study visits across two intervention periods separated by a 4-week washout period.
Fasting blood glucose level
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Measurement of glucose in blood samples

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Fasting blood insulin level
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Measurement of insulin in blood samples

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Fasting blood C-reactive protein level
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Measurement of C-reactive protein in blood samples

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Fasting blood cholesterol (total, LDL, and HDL) level
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Measurement of cholesterol (total, LDL, and HDL) in blood samples (fasting state)

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Fasting blood triglycerides level
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Measurement of triglycerides in blood samples (fasting state)

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Blood Insulin-like growth factor 1 (IGF-1) level
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Measurement of insulin-like growth factor 1 in blood samples

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Height
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

The height will be assessed in centimeters

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.
Body weight
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be weighted in order to have information of their body weight changes in kilograms during the study.

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.
Body mass index
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.

Body mass index will be calculated: BMI=weight (kg)/height (m2)

From enrollment through study completion (up to 16 weeks); assessed at 10 scheduled study visits across two intervention periods separated by a 4-week washout period.
Homeostatic Model Assessment for Insulin Resistance (HOMA_IR)
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

The HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) index will be calculated to measure insulin resistance.

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Triglyceride glucose (TyG)
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.

Triglyceride glucose (TyG) index will be calculated to measure insulin resistance.

From enrollment through study completion (up to 16 weeks); assessed at 6 scheduled study visits across two intervention periods separated by a 4-week washout period.
Dietary pattern
Tijdsspanne: From enrollment through study completion (up to 16 weeks) across two intervention periods separated by a 4-week washout period; 3 days a week, every week (except the washout period)

The dietary pattern will be assessed through food diaries accompanied by a portion guide document.

From enrollment through study completion (up to 16 weeks) across two intervention periods separated by a 4-week washout period; 3 days a week, every week (except the washout period)
Food Frequency Questionnaire
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

The food diaries will be combined with a Food Frequency Questionnaire (FFQ).

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
Body composition using bioelectrical impedance analysis (BIA) - weight
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be have their body weight (kg) measured using Tanita® full body scale.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
BIA - muscle mass
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be have their body muscle mass (% and kg) measured using Tanita® full body scale.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
BIA - body water content
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be have their body water content (% and kg) measured using Tanita® full body scale.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
BIA - fat mass
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be have their body fat mass (% and kg) measured using Tanita® full body scale.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
BIA - basal energy expenditure
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be have their basal energy expenditure (kcal and kJ) measured using Tanita® full body scale.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.
BIA - BMI
Tijdsspanne: From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Participants will be have their BMI in kg/m^2. measured using Tanita® full body scale.

From enrollment through study completion (up to 16 weeks); assessed at 4 scheduled study visits across two intervention periods separated by a 4-week washout period.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 september 2026

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 december 2028

Studieregistratiedata

Eerst ingediend

15 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • PROFIBRE
  • 2026-04807-02 (Andere identificatie: The Swedish Ethical Review Authority)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren